ArticleJournal of neuro-oncology2015
High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype.
Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Attract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas.Neuro-oncology · 2026Review
- The Role of CXCR3 in Nervous System-Related Diseases.Mediators of inflammation · 2024Review
- The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches.Cell death & disease · 2023Review
- Non-neoplastic astrocytes: key players for brain tumor progression.Frontiers in cellular neuroscience · 2023Review
- Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review.Frontiers in cell and developmental biology · 2022Review
- Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Chemoattraction of Neoplastic Glial Cells with CXCL10, CCL2 and CCL11 as a Paradigm for a Promising Therapeutic Approach for Primary Brain Tumors.International journal of molecular sciences · 2021Article
- Review
- Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.Pharmacology & therapeutics · 2021Review
- CXCR3 expression as a prognostic factor in gastric cancer: a meta-analysis.Translational cancer research · 2021Article
- The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.American journal of physiology. Cell physiology · 2020Review
- Screening TCGA database for prognostic genes in lower grade glioma microenvironment.Annals of translational medicine · 2020Article
- LINC00174 is a favorable prognostic biomarker in glioblastoma via promoting proliferative phenotype.Cancer biomarkers : section A of Disease markers · 2020Article
- CXCR3 from chemokine receptor family correlates with immune infiltration and predicts poor survival in osteosarcoma.Bioscience reports · 2019Article
- Review
- The Role of CXCR3 in Neurological Diseases.Current neuropharmacology · 2019Review
- OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma.Frontiers in genetics · 2019Article
- Effect of Vitamin DOpen medicine (Warsaw, Poland) · 2019Article
- CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.OncoTargets and therapy · 2018Article
- The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are a superfamily of small heparin-binding cytokines that induce leukocytes to migrate to sites of inflammation or injury through interacting with specific transmembrane G protein-coupled receptors. Currently, attention is focused on chemokine/chemokine receptor pairs and their ability to promote tumor cell migration and angiogenesis. The chemokine receptor CXCR3 is involved in tumor metastasis and is used as a prognostic biomarker. However, its relationship with the clinicopathological features of primary glioblastoma multiforme (pGBM) and its potential prognostic value have yet to be investigated. Here, we report that high CXCR3 expression conferred poor survival in pGBM patients. Further analysis showed that CXCR3 served as an independent prognostic biomarker for pGBM patients. In addition, functional assays indicated that CXCR3 induced glioma cell invasion. Therefore, this evidence indicates CXCR3 is an independent prognostic factor for pGBM patients and promotes an invasive phenotype, which suggests a new potential biotarget for glioblastoma multiforme therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.